Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
21 mei 2010 - 08:38
Statutaire naam
Pharming Group N.V.
Titel
PHARMING RECEIVES D180 LIST OF OUTSTANDING ISSUES ON RHUCIN MAA
Bericht
Leiden, The Netherlands, May 21, 2010. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) reports that it has received the Day 180 List of Outstanding Issues (LoOI) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Pharming submitted the Marketing Authorization Application (MAA) for Rhucin for the treatment of acute attacks of Hereditary Angioedema (HAE) to the European Medicines Agency in September 2009. The Company responded to the D120 List of Questions in March 2010. After review of the response, the CHMP has now summarized its outstanding questions in the Day 180 LoOI. Pharming plans to submit its response to these questions within the regular one month clock stop period. In line with the regulatory timetable, the CHMP will subsequently reach its final opinion no later than Day 210. More information on this procedure can be found on www.ema.europa.eu.
“There are only a few minor issues left and we are confident that we will be able to provide our response quickly”, said Dr. Bruno Giannetti, Chief Operations Officer of Pharming.
Gerelateerde downloads
Datum laatste update: 05 februari 2025